Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
Anne
A
Ricksten
Lars
L
Palmqvist
Peter
P
Johansson
Björn
B
Andreasson
D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D000986:Antisickling Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*
D000986:Antisickling Agents; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea